HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rejects Sunscreen TEAs, Plans Public Hearing On Ingredient Review

This article was originally published in The Rose Sheet

Executive Summary

FDA announces that it has found data insufficient to affirm the safety of two of the eight pending time-and-extent applications for sunscreen actives – amiloxate and diethylhexyl butamido triazone, marketed under the trade names NeoHeliopan and Uvasorb HEB. The agency invites the public and manufacturers, to submit further information in support of the actives’ safety.

Advertisement

Related Content

Reps Prep Sunscreen Filter Legislation; FDA Frustrated By Backlog

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS018938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel